Alpha 2.0
Login Register
» Authors » Henry H Zhao

Henry H Zhao

Explore the profile of Henry H Zhao including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 101
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
General Medicine
Top 10 Co-Authors
Mark S Shaefer
Lisa L Ross
Benjamin Young
Kathleen E Squires
Edwin DeJesus
Daniel Murphy
Amanda F Peppercorn
Lizette Santiago
Lisa G Patel
Phillip J Yates
Published In
HIV Clin Trials
J Infect Dis
HIV AIDS (Auckl)
AIDS
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
Squires K, Young B, Santiago L, Dretler R, Walmsley S, Zhao H, et al.
HIV AIDS (Auckl) . 2017 Apr; 9:51-61. PMID: 28424561
Purpose: The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment responses. Methods: A total of 369 HIV-infected, antiretroviral-naïve subjects...
2.
Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects
Yates P, Raimonde D, Zhao H, Man C, Steel H, Mehta N, et al.
Antiviral Res . 2016 Aug; 134:144-152. PMID: 27568923
Intravenous zanamivir (IVZ) is a neuraminidase (NA) inhibitor (NAI) under investigation for the treatment of subjects hospitalised with influenza. The study included 130 symptomatic, hospitalised adults with influenza. Subjects received...
3.
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine
Young B, Squires K, Tashima K, Henry K, Schneider S, LaMarca A, et al.
HIV Clin Trials . 2015 Jul; 16(4):125-9. PMID: 26133089
No abstract available.
4.
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial
Wohl D, Bhatti L, Small C, Edelstein H, Zhao H, Margolis D, et al.
PLoS One . 2014 May; 9(5):e96187. PMID: 24825167
Objective: Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study's primary objective was to determine whether abacavir/lamivudine + atazanavir (ABC/3TC+ATV) was virologically non-inferior...
5.
Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study
Marty F, Man C, van der Horst C, Francois B, Garot D, Manez R, et al.
J Infect Dis . 2013 Aug; 209(4):542-50. PMID: 23983212
Background: Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Methods: Patients were treated with intravenous zanamivir 600 mg twice daily, adjusted for renal...
6.
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
Squires K, Young B, DeJesus E, Bellos N, Murphy D, Ward D, et al.
HIV Clin Trials . 2012 Nov; 13(5):233-44. PMID: 23134624
Background: The open-label study ARIES (ClinicalTrials.gov NCT00440947) utilized a ritonavir (/r)-boosted protease inhibitor treatment simplification strategy. Antiretroviral-naïve subjects received abacavir/lamivudine (ABC/3TC) + atazanavir/ ritonavir (ATV/r) from baseline through randomization at...
7.
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
Young B, Squires K, Ross L, Santiago L, Sloan L, Zhao H, et al.
AIDS Res Hum Retroviruses . 2012 Oct; 29(2):350-8. PMID: 23039030
Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk factors and elevated inflammatory biomarkers. Cardiovascular risk and inflammatory biomarkers were evaluated in ARIES, a Phase IIIb/IV...
8.
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
Squires K, Young B, DeJesus E, Bellos N, Murphy D, Zhao H, et al.
AIDS . 2010 Jul; 24(13):2019-27. PMID: 20613461
Background: Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted (/r) protease inhibitor regimen followed by simplification (without RTV) are appealing because they may offer sustained virologic suppression while minimizing...
9.
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients
Squires K, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips D, et al.
HIV Clin Trials . 2010 Jun; 11(2):69-79. PMID: 20542844
Purpose: The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients. Methods: This...